pyrazines has been researched along with Diabetic Glomerulosclerosis in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 18 (64.29) | 24.3611 |
| 2020's | 4 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H; Shi, Y; Xie, H; Zhou, Y | 1 |
| Kosuru, R; Prakash, S; Rai, U; Singh, S; Tiwari, V | 1 |
| Huang, YY; Pan, XD; Wang, ZH; Zheng, Q; Zhuang, Z | 1 |
| Bian, M; Ding, L; Jiang, Z; Li, D; Wu, J; Zeng, Q | 1 |
| Dai, S; Dong, F; Jin, B; Xie, F; Zhang, B; Zhang, T | 1 |
| Flessner, MF; St Peter, WL; Weinhandl, ED | 2 |
| Schütt, M; Steinhoff, J; Süfke, S | 1 |
| Arjona Ferreira, JC; Goldstein, BJ; Golm, GT | 1 |
| Fujita, H; Hayashi, H; Kikuchi, N; Komatsu, K; Komatsu, T; Murayama, H; Narita, T; Ohshiro, H; Sato, S; Taniai, H; Yamada, Y | 1 |
| Fukumoto, M; Hiura, Y; Hosoi, M; Ikuno, Y; Kawasaki, I; Okada, M; Tamai, A; Tanaka, N; Ueno, H; Yakusiji, Y; Yamagami, K; Yoshida, Y | 1 |
| Carr, MC; Handelsman, Y; Jones-Leone, A; Leiter, LA; Scott, R; Stewart, M; Yang, F | 1 |
| Inoue, T; Kyou, C; Morishita, K; Ogawa, T; Taguchi, Y; Umayahara, R; Yonemoto, T | 1 |
| Advani, A; Advani, SL; Azizi, PM; Batchu, SN; Bowskill, BB; Brijmohan, AS; Lee, WL; Liu, Y; Majumder, S; Thai, K; White, KE | 1 |
| Bilan, VP; Jackson, EK; Tofovic, DS | 1 |
| Barth, RN; Cooper, M; Gurk-Turner, C; Hurley, H; KuKuruga, D; Manitpisitkul, W; Philosophe, B; Rasetto, F; Wilson, N | 1 |
| Bloom, D; Djamali, A; Lorentzen, D; Mezrich, JD; Miller, KM; Muth, BL; Pirsch, JD; Sollinger, HW; Torrealba, J | 1 |
| Liang, Y; Si, LY; Xiao, L; Xu, Q; Yang, QH; Zhang, Y | 1 |
| Akehi, Y; Kobayashi, K; Kodera, T; Kudo, T; Nagaishi, R; Nagasako, H; Nomiyama, T; Takenoshita, H; Terawaki, Y; Urata, H; Yanase, T | 1 |
| Alexander, MP; Méndez, GP; Nasr, SH; Rennke, HG; Watson, DC | 1 |
| de Lemos, ET; Fernandes, R; Mascarenhas-Melo, F; Mega, C; Oliveira, J; Reis, F; Teixeira, F; Vala, H | 1 |
| Lin, L; Ni, Q; Wang, B; Wang, X | 1 |
| Arjona Ferreira, JC; Corry, D; Davies, MJ; Goldstein, BJ; Golm, GT; Gonzalez, EJ; Kaufman, KD; Mogensen, CE; Sloan, L; Xu, L | 1 |
| Bakris, GL; Flynn, C | 1 |
| Jackson, EK; Mi, Z | 1 |
| Chen, S; Li, JW; Ma, SX; Wang, Y; Yan, YH | 1 |
| Beyer, KH; Follansbee, MH; Griffith, JW; Vesell, ES | 1 |
| Heidland, A; Hennemann, H; Maidhof, R; Röckel, A | 1 |
5 review(s) available for pyrazines and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Protective effect and possible mechanisms of ligustrazine isolated from Ligusticum wallichii on nephropathy in rats with diabetes: A preclinical systematic review and meta-analysis.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ligusticum; Protective Agents; Pyrazines; Rats | 2020 |
Efficacy and safety of Salvia miltiorrhiza (Salvia miltiorrhiza Bunge) and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease: A systematic review and meta-analysis.
Topics: Diabetic Nephropathies; Humans; Plant Extracts; Pyrazines; Salvia miltiorrhiza | 2021 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous | 2011 |
Meta-analysis of the clinical effect of ligustrazine on diabetic nephropathy.
Topics: Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Drugs, Chinese Herbal; Humans; Kidney; Ligusticum; Phytotherapy; Proteinuria; Pyrazines | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
5 trial(s) available for pyrazines and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Chemokine CXCL12; Cross-Over Studies; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Piperidines; Pyrazines; Receptor, Angiotensin, Type 1; Sitagliptin Phosphate; Triazoles; Up-Regulation; Uracil | 2014 |
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Renal Insufficiency; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Japan; Kidney; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Asia; Asian People; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Pyrazines; Renal Dialysis; Sitagliptin Phosphate; Triazoles | 2013 |
18 other study(ies) available for pyrazines and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
TMBIM6 promotes diabetic tubular epithelial cell survival and albumin endocytosis by inhibiting the endoplasmic reticulum stress sensor, IRE1α.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Diabetes Mellitus; Diabetic Nephropathies; Endocytosis; Endoplasmic Reticulum Stress; Endoribonucleases; Epithelial Cells; Fluorescein-5-isothiocyanate; Glucose; Imidazoles; Low Density Lipoprotein Receptor-Related Protein-2; Membrane Proteins; Mice; Naphthalenes; Protein Serine-Threonine Kinases; Pyrazines | 2022 |
Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Kidney; Kidney Failure, Chronic; Male; Oxidative Stress; Protective Agents; Proto-Oncogene Proteins c-akt; Pyrazines; Rats, Wistar; Signal Transduction | 2019 |
Oltipraz Prevents High Glucose-Induced Oxidative Stress and Apoptosis in RSC96 Cells through the Nrf2/NQO1 Signalling Pathway.
Topics: Animals; Apoptosis; Cell Line; Diabetic Nephropathies; Glucose; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Oxidative Stress; Pyrazines; Rats; Thiones; Thiophenes | 2020 |
Sitagliptin--another option for managing type 2 diabetes in dialysis patients?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
[Diabetes treatment in patients with chronic kidney disease].
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Kidney Function Tests; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
In reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Triazoles | 2013 |
Primary objective of study of sitagliptin in patients with ESRD on dialysis.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Triazoles | 2013 |
Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate.
Topics: Albuminuria; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Prostaglandin I2 Receptor Agonism Preserves β-Cell Function and Attenuates Albuminuria Through Nephrin-Dependent Mechanisms.
Topics: Acetamides; Acetates; Animals; Cell Line; Cell Survival; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Membrane Proteins; Mice, Inbred C57BL; Mice, Knockout; Mutation; Phosphorylation; Podocytes; Prodrugs; Protein Processing, Post-Translational; Pyrazines; Receptors, Epoprostenol; Renal Insufficiency; RNA Interference | 2016 |
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.
Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Hypertension; Kidney; Male; Metabolic Syndrome; Proteinuria; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sitagliptin Phosphate; Triazoles; Vasoconstriction; Vasoconstrictor Agents | 2010 |
Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
Topics: Adult; Antilymphocyte Serum; Boronic Acids; Bortezomib; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diuresis; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Pancreas Transplantation; Plasmapheresis; Protease Inhibitors; Pyrazines; Renal Dialysis; Reoperation; Tissue Donors; Treatment Outcome | 2009 |
Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation.
Topics: Acute Disease; Adult; Boronic Acids; Bortezomib; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diuresis; Drug Resistance, Multiple; Graft Rejection; Humans; Immunization; Kidney Transplantation; Male; Pancreas Transplantation; Protease Inhibitors; Pyrazines | 2009 |
Protective effect of tetramethylpyrazine isolated from Ligusticum chuanxiong on nephropathy in rats with streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Ligusticum; Male; Phytotherapy; Plant Extracts; Protective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Endothelial Growth Factor A | 2011 |
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Insulin; Kidney Glomerulus; Lipid Peroxidation; Lipids; Male; Obesity; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension.
Topics: Angiotensin II; Animals; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Hypertension, Renal; Kidney; Male; Neuropeptide Y; Peptide Fragments; Pyrazines; Rats; Rats, Inbred SHR; Renal Circulation; Sitagliptin Phosphate; Sympathetic Nervous System; Triazoles; Vasoconstrictor Agents | 2008 |
Effect of new thromboxane A2 synthesis inhibitor tetramethyl-pyrazine on pancreatic transplantation in diabetic rats.
Topics: Albuminuria; Animals; Benzofurans; beta 2-Microglobulin; Cyclosporine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Immunosuppressive Agents; Kidney; Organ Size; Pancreas Transplantation; Pyrazines; Rats; Rats, Wistar; Thromboxane A2; Thromboxane-A Synthase; Transplantation, Isogeneic | 1996 |
Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Guanidines; Hydrochlorothiazide; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Kidney; Kidney Function Tests; Male; Molecular Weight; Pyrazines; Rats; Rats, Sprague-Dawley; Serum Albumin; Streptozocin | 1997 |
[Divergence of renal sodium and magnesium excretion following administration of trometamol (trisbuffer), amiloroide-HCL, acetazolamide and parathormone -- a result of urinary alkalization?].
Topics: Acetazolamide; Amidines; Buffers; Diabetic Nephropathies; Diuresis; Diuretics; Glomerular Filtration Rate; Glomerulonephritis; Humans; Hydrogen-Ion Concentration; Kidney; Magnesium; Natriuresis; Parathyroid Hormone; Potassium; Pyelonephritis; Pyrazines; Tromethamine; Urine | 1970 |